Please assess the completion status of the following clinical trial:

Trial Title: ARTEMIS Peanut Allergy In Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 4 to 17 years, inclusive~* Clinical history of allergy to peanuts~* Serum SPT ≥ 3 mm greater than control and/or psIgE ≥ 0.35 kUa/L~* Dose limiting symptoms after consuming a single dose of peanut protein ≤ 300 mg~* Written informed consent from the subject's parent/guardian~* Written assent from the subject as appropriate (per local regulatory requirements)~* Use of effective birth control by sexually active female subjects of childbearing potential~Key Exclusion Criteria:~* History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension~* History of severe asthma (NHLBI criteria steps 5 or 6), or mild to moderate asthma (2007 NHLBI criteria steps 1-4) that is uncontrolled or difficult to control~* History of severe or life threatening episode of anaphylaxis or anaphylactic shock within 60 days of screening~* History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology~* History of a mast cell disorder, including mastocytosis, urticaria pigmentosa, chronic idiopathic or chronic physical urticaria beyond simple dermatographism (e.g., cold urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema~* Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- AR101 (Type: ACTIVE_COMPARATOR): AR101 powder provided in capsules \& sachets
- Placebo (Type: PLACEBO_COMPARATOR): Placebo powder provided in capsules \& sachets

Based on this trial design, predict the completion outcome and termination type (if applicable).